What's new? Log in Free sign up

Filing search / Pulmatrix, Inc. / "Litigation"

Search information

Pulmatrix, Inc.

Companies

"Litigation"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

154 results

Newest first Best match first

PULM Pulmatrix, Inc.

Quarterly report

and disbursements and costs of investigation, litigation, settlement, judgment, interest and penalties). 1.10 “Material” shall mean any or all … and executed by MANNKIND and PULMATRIX. 13.10 Jurisdiction. Each Party irrevocably and unconditionally agrees that it will not commence any action, litigation

13 Aug 24

9:20am

PULM Pulmatrix, Inc.

Quarterly report

. Legal Proceedings. From time to time, we may be involved in litigation that arises through the normal course of business. As of the date … , nor are we aware of any such threatened or pending litigation or any such proceedings known to be contemplated by governmental authorities. We

13 Aug 24

9:20am

PULM Pulmatrix, Inc.

Quarterly report

be entitled to retain one (1) copy MannKind’s Confidential Information solely for litigation or archival purposes and Pulmatrix shall not be required … be entitled to retain one (1) copy Pulmatrix’s Confidential Information solely for litigation or archival purposes and MannKind shall not be required

13 Aug 24

9:20am

PULM Pulmatrix, Inc.

Quarterly report

be involved in litigation that arises through the normal course of business. As of the date of this filing, we are not aware of any material legal proceedings … litigation or any such proceedings known to be contemplated by governmental authorities. We are not aware of any material proceedings in which any of our

10 May 24

9:20am

PULM Pulmatrix, Inc.

products only to be subject to significant delay and patent litigation before its products may be commercialized. Orphan Drug Designation The Orphan … ’ former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims

28 Mar 24

9:21am

Quarterly report

9 Nov 23

9:20am

iuw9cyvy2mr8 zjv3

Quarterly report

10 Aug 23

9:20am

Definitive proxy

2 Jun 23

9:20am

1cvb54925px05 s7

Quarterly report

12 May 23

9:20am

30 Mar 23

9:20am

pj9z3ygemyy nm4nug9

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Quarterly report

10 Nov 22

9:20am

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

czrf8js619d1u43n4a

Quarterly report

10 Aug 22

9:20am

1nj4m rkc4awiv05h08q

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

cg0wk20lyt6ngb3bb

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

Quarterly report

12 May 22

9:20am

nmue0is6fop1v7adyr

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

ebw6y2y9ypitx3lu859

Definitive proxy

29 Apr 22

4:06pm

Prev
1
2
3
4
5
...
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.